Skip to main content

Loading market data...

NBIX

Neurocrine Biosciences, Inc.

NASDAQ • United states

$141.31

-$0.69

(-0.49%)

Source: Yahoo Finance · Quote time Oct 21, 2026 20:00 GMT+0000

Management
Credibility
Score

Neurocrine Biosciences, Inc. (NBIX)

Unavailable

Quotes may be delayed

$14.36B

Market Cap

812,563

Volume

20.4

P/E Ratio

Unavailable

Div Yield

Neurocrine Biosciences, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

15 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Neurocrine Biosciences, Inc..

29 Sep 2026

Neurocrine Biosciences, Inc. reported A director or senior management change or compensation event

Neurocrine Biosciences, Inc. filed an 8-K covering a director or senior management change or compensation event.

1 Aug 2026

Neurocrine Biosciences, Inc. securities registration filing

Neurocrine Biosciences, Inc. filed a registration or prospectus document concerning securities.

31 Jul 2026

Neurocrine Biosciences, Inc. filed Form 10-Q

Neurocrine Biosciences, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

31 Jul 2026

Neurocrine Biosciences, Inc. reported Operating or financial results

Neurocrine Biosciences, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$332.40M

Total assets (USD)$5.36B

Total liabilities (USD)$1.67B

Shareholders' equity (USD)$3.69B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$959.00M	$151.50M	$144.40M	$1.39	10-Q · 31 Jul 2026
Q1 2026	$814.50M	$193.40M	$197.90M	$1.91	10-Q · 5 May 2026
Q4 2025	$805.50M	$210.90M	$153.70M	Unavailable	10-K · 11 Feb 2026
Q3 2025	$794.90M	$239.00M	$209.50M	$2.04	10-Q · 28 Oct 2025
Q2 2025	$687.50M	$145.60M	$107.50M	$1.06	10-Q · 30 Jul 2025
Q1 2025	$572.60M	$23.60M	$7.90M	$0.08	10-Q · 5 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $207.28

46.7% upside potential

📈

Strong Buy

Unavailable

👍

Buy

22

⏸️

Hold

3

📉

Sell

0

25 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 23:49 UTC Targets range 150.00–253.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

14

Sep 2026

Boyer David W.

Chief Corp. Affairs Officer

Open-market sale

$157.45 per share

826 shares

11

Sep 2026

Onyia Jude

Chief Scientific Officer

Grant or award

Unavailable per share

3,587 shares

11

Sep 2026

Onyia Jude

Chief Scientific Officer

Tax withholding

$156.22 per share

1,936 shares

11

Sep 2026

Lippoldt Darin

Chief Legal Officer

Grant or award

Unavailable per share

4,483 shares

11

Sep 2026

Lippoldt Darin

Chief Legal Officer

Tax withholding

$156.22 per share

2,419 shares

11

Sep 2026

Keswani Sanjay Chandru

Chief Medical Officer

Grant or award

Unavailable per share

3,914 shares

11

Sep 2026

Keswani Sanjay Chandru

Chief Medical Officer

Tax withholding

$156.22 per share

2,112 shares

11

Sep 2026

GORMAN KEVIN CHARLES

Director

Grant or award

Unavailable per share

14,343 shares

11

Sep 2026

GORMAN KEVIN CHARLES

Director

Tax withholding

$156.22 per share

7,839 shares

11

Sep 2026

Gano Kyle

Director, Chief Executive Officer

Grant or award

Unavailable per share

8,117 shares

Top Shareholders

Blackrock, Inc.

13,711,607 shares

2.435% change

6/30/2026

Vanguard Group Inc

9,700,301 shares

-0.064% change

12/31/2025

Jpmorgan Chase & Co

6,398,674 shares

17.578% change

6/30/2026

Dodge & Cox

5,584,707 shares

2.265% change

6/30/2026

Vanguard Portfolio Management Llc

4,974,083 shares

5.242% change

6/30/2026

Vanguard Capital Management Llc

4,545,339 shares

0.741% change

6/30/2026

State Street Corp

4,385,598 shares

0.714% change

6/30/2026

Aqr Capital Management Llc

3,818,037 shares

-22.696% change

6/30/2026

Renaissance Technologies Llc

2,335,897 shares

-3.431% change

6/30/2026

Geode Capital Management, Llc

2,138,777 shares

0.099% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 23:49 UTC· 7 hours ago

Research coverage and investment tools

Neurocrine Biosciences, Inc. (NBIX) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$141.31 on 21 Oct 2026. That is 30% of the way from its 52-week low of US$122.14 to its 52-week high of US$186.12. Its market capitalisation was US$14.36 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$959.00M	$151.50M	$144.40M	$1.39	—	15.8%	$128.60M	10-Q · 31 Jul 2026 (opens in a new tab)
Q1 2026	$814.50M	$193.40M	$197.90M	$1.91	—	23.7%	$136.70M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$805.50M	$210.90M	$153.70M	Unavailable	—	26.2%	$390.80M	10-K · 11 Feb 2026 (opens in a new tab)
Q3 2025	$794.90M	$239.00M	$209.50M	$2.04	—	30.1%	$214.30M	10-Q · 28 Oct 2025 (opens in a new tab)
Q2 2025	$687.50M	$145.60M	$107.50M	$1.06	—	21.2%	$89.50M	10-Q · 30 Jul 2025 (opens in a new tab)
Q1 2025	$572.60M	$23.60M	$7.90M	$0.08	—	4.1%	$54.10M	10-Q · 5 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/30/2026	$2.36	$1.88	+25.5%
Mar 2026	5/5/2026	$1.41	$1.28	+10.2%
Dec 2025	2/11/2026	$1.43	$1.78	-19.7%
Sep 2025	10/28/2025	$2.04	$1.58	+29.1%

Cash and equivalents: $332.40M
Total assets: $5.36B
Total liabilities: $1.67B
Shareholders' equity: $3.69B

SCHEDULE 13G/A · 15 Oct 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Neurocrine Biosciences, Inc..
8-K · 29 Sep 2026 · Management change

Neurocrine Biosciences, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Neurocrine Biosciences, Inc. filed an 8-K covering a director or senior management change or compensation event.
S-8 · 1 Aug 2026

Neurocrine Biosciences, Inc. securities registration filing (opens in a new tab)

Neurocrine Biosciences, Inc. filed a registration or prospectus document concerning securities.
10-Q · 31 Jul 2026

Neurocrine Biosciences, Inc. filed Form 10-Q (opens in a new tab)

Neurocrine Biosciences, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 31 Jul 2026

Neurocrine Biosciences, Inc. reported Operating or financial results (opens in a new tab)

Neurocrine Biosciences, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Boyer David W. Chief Corp. Affairs Officer	14 Sep 2026	Open-market sale (S)	−826	$157.45	Form 4 (opens in a new tab)
Onyia Jude Chief Scientific Officer	11 Sep 2026	Grant or award (A)	+3,587	—	Form 4 (opens in a new tab)
Onyia Jude Chief Scientific Officer	11 Sep 2026	Tax withholding (F)	−1,936	$156.22	Form 4 (opens in a new tab)
Lippoldt Darin Chief Legal Officer	11 Sep 2026	Grant or award (A)	+4,483	—	Form 4 (opens in a new tab)
Lippoldt Darin Chief Legal Officer	11 Sep 2026	Tax withholding (F)	−2,419	$156.22	Form 4 (opens in a new tab)
Keswani Sanjay Chandru Chief Medical Officer	11 Sep 2026	Grant or award (A)	+3,914	—	Form 4 (opens in a new tab)
Keswani Sanjay Chandru Chief Medical Officer	11 Sep 2026	Tax withholding (F)	−2,112	$156.22	Form 4 (opens in a new tab)
GORMAN KEVIN CHARLES Director	11 Sep 2026	Grant or award (A)	+14,343	—	Form 4 (opens in a new tab)
GORMAN KEVIN CHARLES Director	11 Sep 2026	Tax withholding (F)	−7,839	$156.22	Form 4 (opens in a new tab)
Gano Kyle Director, Chief Executive Officer	11 Sep 2026	Grant or award (A)	+8,117	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	13,711,607	2.435%
Vanguard Group Inc	12/31/2025	9,700,301	-0.064%
Jpmorgan Chase & Co	6/30/2026	6,398,674	17.578%
Dodge & Cox	6/30/2026	5,584,707	2.265%
Vanguard Portfolio Management Llc	6/30/2026	4,974,083	5.242%
Vanguard Capital Management Llc	6/30/2026	4,545,339	0.741%
State Street Corp	6/30/2026	4,385,598	0.714%
Aqr Capital Management Llc	6/30/2026	3,818,037	-22.696%
Renaissance Technologies Llc	6/30/2026	2,335,897	-3.431%
Geode Capital Management, Llc	6/30/2026	2,138,777	0.099%

Previous close: 142.00 USD
Day range: 140.84 – 142.77 USD
52-week range: 122.14 – 186.12 USD
Volume: 812,563
Market cap: $14.36B
Average volume: 1,250,835
P/E ratio: 20.4
EPS (FY 2025, diluted): 4.67 USD
Shares outstanding: 101.65M
Beta (5Y monthly): 0.33

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 20:00 UTC· 11 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:25 UTC· 50 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for NBIX yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.